Overview

An Observational Study on Renal Function in Kidney Transplant Participants on Immunosuppressive Therapy Containing Mycophenolate Mofetil

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
0
Participant gender:
All
Summary
This observational study will evaluate renal function in participants who underwent renal allograft transplantation and are started on combined immunosuppressive treatment containing mycophenolate mofetil (CellCept). Eligible participants will be followed for 12 months following transplantation.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Immunosuppressive Agents
Mycophenolate mofetil
Mycophenolic Acid
Criteria
Inclusion Criteria:

- Participants who underwent renal allograft transplantation and are started on combined
immunosuppressive treatment containing mycophenolate mofetil in accordance with the
indication provided by the SmPC of mycophenolate mofetil

- Date of study enrollment is the date of kidney transplantation

Exclusion Criteria:

- Contraindication included in the SmPC for capecitabine (Xeloda) prevailed, like:
Hypersensitivity to active ingredient or any of the excipients of the product;
Pregnancy and lactation